Kymera Therapeutics, Inc. (KYMR) has 25 SEC Form 4 insider filings on record in the last 90 days. No insider purchases were filed — 11 sales totalling $379.8M. Most recent filing: Sept. 4, 2026.
| Date | Insider | Value | Shares | Stake | Pre-planned | Links |
|---|---|---|---|---|---|---|
| Sept. 4, 2026 | Adams Brian Chief Legal Officer | −$744,297 | 6,371 | −11% | No | |
|
|
||||||
| July 27, 2026 | Rooney Terence Chief Medical Officer | $0 | 114,000 | +100% | No | |
|
|
||||||
| July 7, 2026 | Mainolfi Nello Chief Executive Officer | $5,846,000 | 150,000 | 0% | Yes | |
|
|
||||||
| July 2, 2026 filed June 30, 2026 | Jacobs Bruce N. Chief Financial Officer | −$1,808,513 | 199,865 | −100% | Yes | |
|
|
||||||
| July 2, 2026 filed July 1, 2026 | Goodman Noah Chief Business Officer | −$387,329 | 3,389 | −7% | Yes | |
|
|
||||||
Showing the 5 most recent of 25 filings in the last 90 days.
Form 4 is the filing company officers, directors and 10% shareholders must submit to the SEC within two business days of trading their own company's stock. Open-market purchases generally carry more signal than sales, which are often scheduled in advance. More on how this works.
Real-time Telegram alerts the moment a Form 4 is filed. Filings shown here are delayed by 72 hours.
Start free